Literature DB >> 16184606

Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease.

V Maglione1, P Giallonardo, M Cannella, T Martino, L Frati, F Squitieri.   

Abstract

Huntington's disease (HD) may manifest at an earlier age in affected offspring than in transmitting parents. Earlier onset in successive generations (anticipation) only partially depends on intergenerational parent-child elongation of the CAG expanded mutation. An aberrant amplification of adenosine A(2A) receptor signaling documented in peripheral blood cells of subjects with HD implies that this cellular dysfunction may be related to clinical and genetic features. Prompted by evidence of higher receptor densities in siblings of HD subjects with stronger onset anticipation, in this study we investigated a possible relationship between A(2A) receptor densities and age at onset. We measured adenosine A(2A) receptor densities in blood cell platelets from 32 patients with HD and healthy control siblings, and sought a possible linear correlation between maximum platelet A(2A) receptor binding (B(max)) values for the whole cohort of HD subjects and anticipation in years. The increased B(max) values for the 32 subjects with HD (220 in patients vs. 137 in healthy control subjects, P = 0.0001) correlated significantly with anticipation in years (r2, 0.48, P = 0.0001 by linear correlation analysis). An increased platelet A(2A) receptor B(max) may belong in a cascade of toxic events leading to earlier onset of HD: as such it could be a useful marker of onset anticipation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16184606     DOI: 10.1002/ajmg.b.30223

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  11 in total

Review 1.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

2.  Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients.

Authors:  Kuo-Hsuan Chang; Yi-Chun Chen; Yih-Ru Wu; Wan-Fen Lee; Chiung-Mei Chen
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

3.  De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease.

Authors:  Alba Di Pardo; Abdul Basit; Andrea Armirotti; Enrico Amico; Salvatore Castaldo; Giuseppe Pepe; Federico Marracino; Fabio Buttari; Anna F Digilio; Vittorio Maglione
Journal:  Front Neurosci       Date:  2017-12-19       Impact factor: 4.677

4.  Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.

Authors:  Chiung-Mei Chen; Yih-Ru Wu; Kuo-Hsuan Chang
Journal:  Int J Mol Sci       Date:  2017-11-21       Impact factor: 5.923

5.  Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients.

Authors:  Kuo-Hsuan Chang; Yih-Ru Wu; Chiung-Mei Chen
Journal:  Orphanet J Rare Dis       Date:  2017-12-19       Impact factor: 4.123

Review 6.  Platelets in Neurodegenerative Conditions-Friend or Foe?

Authors:  Odette Leiter; Tara L Walker
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 7.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

8.  Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

Authors:  Albino Carrizzo; Alba Di Pardo; Vittorio Maglione; Antonio Damato; Enrico Amico; Luigi Formisano; Carmine Vecchione; Ferdinando Squitieri
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

Review 9.  Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders.

Authors:  Alba Di Pardo; Vittorio Maglione
Journal:  Front Neurosci       Date:  2018-04-17       Impact factor: 4.677

Review 10.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.